💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company’s segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling business, fairly priced.
Jubilant Pharmova is scored on the pharma / healthcare framework. It keeps a slim 4.8% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 3.09× reported profit. Free cash flow is worth about -0.2% of its market value.
Book value has grown 10%/yr. Return on equity is a weak 5.6%. In the latest quarter profit fell 53% versus the prior quarter.
At 37× earnings, the stock sits at the 49th percentile of its own 2.6-year range — the middle of where it has historically traded. Today's price already implies ~19%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 42.55 | — | — |
| P/B | 2.11 | 4.1 | better |
| EV/EBITDA | 14.14 | 19.33 | better |
| ROE | 5.62 | — | — |
| ROCE | 6.41 | 14.41 | worse |
| ROA | 2.26 | 1.64 | better |
| Quick Ratio | 1.13 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 10% CAGR — growing but slowly. Growth is accelerating — latest year outpaced the prior year's rate.
1 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a -52% swing — check if it's a one-off or structural.
Operating margin has expanded from 0% to 7% — the business is keeping more of each rupee earned.
ROE at 6% — modest; the capital isn't working hard. Capital efficiency improving — ROE up 7pp across the window.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. Profit grew faster than EPS (134% vs 127%) — share dilution is eroding per-share value. 127% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 3.1× PAT — earnings are well-backed by cash; strong accrual quality. Raising capital despite positive cash flow — could signal expansion plans or opportunistic fundraising.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Run-rate stepping up — recent quarters average 11% above earlier ones.
Profit fell 53% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly margins are compressing (6% → 3%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 2.6y median.
Promoters at 47.7% — dispersed ownership; institutional flows drive the stock.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.